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Abstract
Background: Parkinsonian symptoms have been associated with increased morbidity and
mortality. Several studies have reported on the prevalence of signs and symptoms. Symptoms
questionnaires can identify potential PD cases for further neurological examination to save
resources. They can also provide information about how much of the population reports specific
signs and symptoms. The objective of the study was to determine the self-reported prevalence of
parkinsonian symptoms from a questionnaire, and to examine their association with age and self-
reported Parkinson's disease in a large cohort.
Methods: A cross-sectional study was conducted within a sub-cohort of the EPIC-Norfolk
(European Prospective Investigation of Cancer) cohort study.
Results: The prevalence of six self-reported parkinsonian symptoms are reported for 11539
individuals who answered all symptoms questions (62% of sub-cohort): rest tremor (4%), difficulty
starting to walk (4%), difficulty getting out of a chair (6%), slower walking (34%), smaller handwriting
(micrographia- 9%), and less acute sense of smell (olfactory dysfunction- 9%). The presence of
individual symptoms increased with age except for difficulty getting out of a chair.
Conclusion: The results support previous findings that the presence of self-reported parkinsonian
symptoms is strongly associated with age and self-reported PD diagnosis. The data also provide
information regarding the prevalence of symptoms in a large, younger population of adults than
previously reported in the literature.
Background
Parkinsonian symptoms have been associated with
increased morbidity and mortality in Alzheimer's disease
and in individuals without dementia [1,2]. In one pro-
spective cohort study, progression in gait disturbance,
measured with the UPDRS, was associated with mortality
[3]. Individuals with Parkinson's Disease (PD) by defini-
tion will have a greater prevalence of symptoms and signs
than those without PD, and the age-dependence of par-
kinsonism predicts that older age groups will have higher
proportions of reported signs and symptoms. Several
studies have reported the presence of parkinsonian signs
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of PD [1,4-11].
The diagnosis of PD is based on clinical signs because
there is currently no conclusive diagnostic test available
[12]. Clinical characteristics manifest only when the sub-
stantia nigral cell loss has reached a threshold of 60 to
80%, and most parkinsonian symptoms and signs are not
specific to PD [12-14].
There are four cardinal motor signs of Parkinsonism: rest-
ing tremor at 4–6 Hertz, bradykinesia, rigidity, and
impaired postural and righting reflexes. Other PD symp-
toms include: shuffling gait, cogwheel rigidity, unilateral
onset, persistent asymmetry in severity, micrographia,
masked facies, and retropulsion [15]. Reduced olfactory
function has recently been suggested as a feature indicat-
ing pre-clinical PD, although it is not specific to PD [16-
19].
The purpose of this study was to determine the prevalence
of self-reported parkinsonian symptoms within a sub-
cohort of EPIC-Norfolk [20]. We report the prevalence of
six symptoms by age and PD status.
Methods
The design and methods of the EPIC-Norfolk cohort study
have been described previously [20]. We provide a brief
summary of the details regarding the sub-cohort used for
the current analyses. The cohort includes men and women
who were aged between 45 and 74 years at the time they
entered the study. Subjects were recruited through
selected General Practitioner (GP) practices in Norfolk,
United Kingdom. Invitations were sent to 77 630 individ-
uals and the response rate was 39% (N = 30 447). The
main purpose of cohort recruitment was to conduct a pro-
spective study of healthy participants willing to be fol-
lowed up over time, so the aim was not to recruit a
representative population sample. Nevertheless, the EPIC
population is similar in age, sex and race to the national
sample in the Health Survey for England though with a
slightly lower proportion of current smokers.
The population used for studying Parkinsonian symp-
toms in the EPIC cohort includes only those that com-
pleted a second health questionnaire eighteen months
after baseline (N = 18 465), when there were specific ques-
tions about parkinsonian symptoms. Baseline characteris-
tics are reported for the total cohort, individuals who did
not respond to the Parkinson's questionnaire, and those
in the current sub-cohort (Table 1).
An algorithm was created to relate the questionnaire to
specific parkinsonian symptoms (Table 2).
PD case ascertainment was based on self-report at baseline
or 18-month follow-up questionnaire, ongoing reports of
ICD-9 diagnosis of PD from computerised hospital dis-
charge records, and ongoing searches of death certificates
reports for mention of PD. Diagnostic criteria were not
standardised and relied on individual clinician opinions.
Data analyses
Analyses were conducted using Intercooled STATA 7.0.
The symptom prevalence is reported for the subset of indi-
viduals who answered all symptom questions (62%), and
for the total sub-cohort with missing responses as a
separate response category. Chi-square tests for trend were
used to examine the differences in reported parkinsonian
symptom prevalence across 10-year age groups.
Table 1: Comparison of baseline characteristics between the total EPIC-Norfolk cohort and those completing the 18-month follow-up 
health questionnaire (current sub-cohort).
Baseline Characteristics 2nd health questionnaire (Sub-
cohort)
Non-respondents to the 2nd health 
questionnaire
Total Cohort
Total Number 18465 11980 30445
Age (Years), Mean ± SD 59.0 ± 9.2 60.0 ± 9.7 59.4 ± 9.4
Male (%) 8029 (43.5) 5672 (47.3) 13701 (45.0)
Female (%) 10436 (56.5) 6308 (52.7) 16744 (55.0)
Smoking Status N (%)
Current 1873 (10.2) 1858 (15.7) 3731 (12.4)
Former 7548 (41.2) 5158 (43.6) 12706 (42.1)
Never 8897 (48.6) 4824 (40.7) 13721 (45.5)
Education Level
Below O level 7067 (38.3) 5585 (46.8) 12652 (41.6)
O level 2441 (13.2) 1339 (11.2) 3780 (12.4)
A level 6468 (35.0) 3806 (31.9) 10274 (33.8)
Degree 2489 (13.5) 1216 (10.2) 3705 (12.2)Page 2 of 9
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Of 30 447 study participants, the sub-cohort used for the
present analyses included 18 465 subjects that were fol-
lowed up at least through the health questionnaire eight-
een months after baseline (61%). There were 8029 men
(43%), mean age 59.6 ± 9.1 years and 10 436 women,
mean age 58.5 ± 9.2 years. A comparison of the sub-
cohort with the non-respondents indicates that the non-
respondents were older, less educated, and had a higher
proportion of males and smokers (Table 1). There were 39
(0.9%) men and 30 (0.3%) women with prevalent Par-
kinson's disease in the sub-cohort identified through
medical records, death certificates and self-report. Hospi-
tal records found only one additional baseline case, and
death certificates revealed two previously unreported
cases.
Only 11 539 (62%) of the participants answered all ques-
tions regarding parkinsonian symptoms on the follow-up
questionnaire, including 53 (30 men, 23 women) PD
cases. Symptom prevalence is reported excluding individ-
uals with incomplete responses. The prevalences are also
reported for the total sub-cohort for individuals answer-
ing yes or no, or missing a response. An exploration of the
pattern of missing data revealed that most individuals
either answered all, none, all except one, or only one of
the questions (Table 3).
The parkinsonian symptoms were each reported by less
than 10% of individuals except for slower walking, which
was present in 34% of the individuals who answered all
symptoms questions (Table 4). When missing answers
were included as a response category, the prevalence of
slower walking went down to 28%. The prevalence of
slower walking which ranged from 11% to 71% in those
with complete responses (8% to 56% including missing
answers) from youngest to oldest age groups.
The proportion of subjects reporting each symptom sig-
nificantly increased with age, with the exception of diffi-
culty getting out of a chair. Difficulty walking was
relatively constant across the age groups, until the age of
80 when there was a sharp increase. The age trends were
similar for males and females, with the exception of diffi-
culty getting out of a chair, which was age-dependent for
males but less so for females (Results not shown). The per-
centage of PD cases reporting each parkinsonian symp-
tom ranged from 34% to 85% (30% to 83% including
missing responses), and as expected all symptoms were
reported in proportionally more PD than non-PD subjects
(Table 4).
The proportion of individuals self-reporting PD increased
with age. The prevalence of PD in the individuals
answering all symptoms questions was 0.46%, and 0.37%
in the total sub-cohort (Table 4). Anti-parkinsonian med-
ication use was recorded according to the British National
Formulary. Nineteen identified PD cases were using at
least one of selegiline, pergolide, and levodopa. The use of
bromocriptine and procyclidine, which are not specific
treatments for PD, was reported by nine individuals with-
out self-reported PD.
The sensitivity and specificity for each symptom question
as well as cumulative numbers of symptoms questions are
reported in Table 5. The question with the highest sensi-
tivity (85%) asked about walking slower, but the specifi-
city was very low (66%). If a positive response to any of
the six symptoms questions was defined as screening pos-
itive, then the sensitivity was 96% and specificity was
Table 2: Summary of questions related to parkinsonian symptoms from the follow-up questionnaire
Parkinsonian symptom Present if answered yes to these questions
Resting Tremor Tremor or shakiness in hands? When relaxed?
Difficulty walking Difficulty in starting to walk? Not due to arthritis?
Difficulty getting out of a chair Difficulty getting out of a chair? Not due to arthritis?
Walking slower Has walking become slower?
Micrographia Has handwriting changed? Smaller?
Olfactory dysfunction Has sense of smell changed? Less acute?
Table 3: Patterns of missing responses according to the order of 
questions on the questionnaire (N = 18 465)
Order of 6 symptom questions N (% of total)
Answered all 11539 (62.5)
Answered none 1196 (6.5)
Answered first question only 2160 (11.7)
Missing one question only 2219 (12.0)
Miscellaneous missing 1351 (7.3)Page 3 of 9
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Age Group, Years (N)
Excluding individuals with any missing symptom answers
Symptom 40–49 (818) 50–59 (4008) 60–69 (3849) 70–79 (2803) 80+ (61) All Ages 
(11 539)
P- value for 
age trend*
PD Cases 
(53)
Resting Tremor 3.9 (32) 3.6 (144) 4.3 (166) 5.4 (150) 6.6 (4) 4.3 (496) 0.0008 49.1 (26)
Difficulty Walking 4.7 (38) 5.0 (200) 3.8 (147) 3.9 (110) 6.6 (4) 4.3 (499) 0.0435 35.9 (19)
Difficulty Chair 6.6 (54) 6.4 (255) 5.7 (220) 7.2 (203) 8.2 (5) 6.4 (737) 0.3255 39.6 (21)
Walking Slower 11.3 (92) 19.6 (787) 35.9 (1383) 57.3 (1607) 70.5 (43) 33.9 (3912) <0.0001 84.9 (45)
Micrographia 5.1 (42) 5.5 (219) 8.7 (336) 16.2 (454) 27.9 (17) 9.3 (1068) <0.0001 73.6 (39)
Smell less acute 7.7 (63) 7.9 (315) 9.3 (357) 11.4 (319) 13.1 (8) 9.2 (1062) <0.0001 34.0 (18)
Any of symptoms 25.7 (210) 32.6 (1306) 46.1 (1775) 65.1 (1826) 77.1 (47) 44.8 (5164) <0.0001 96.2 (51)
Self-reported PD 0.12 (1) 0.35 (14) 0.36 (14) 0.82 (23) 1.64 (1) 0.46 (53) 0.0012
Including Missing answers as a separate category
Symptom 40–49 (1342) 50–59 (6341) 60–69 (6063) 70–79 (4608) 80+ (111) All Ages 
(18 465)
P- value for 
age trend*
PD Cases 
(69)
Resting Tremor
Yes 3.5 (47) 3.2 (203) 3.7 (224) 4.5 (206) 6.3 (7) 3.7 (687) 0.0026 42.0 (29)
No 84.8 (1138) 87.1 (5526) 88.8 (5385) 87.9 (4052) 83.8 (93) 87.7 (16194) 50.7 (35)
Missing 11.7 (157) 9.7 (612) 7.5 (454) 7.6 (350) 9.9 (11) 8.6 (1584) 7.3 (5)
Difficulty Walking
Yes 3.4 (46) 4.7 (295) 3.4 (208) 3.4 (157) 6.3 (7) 3.9 (713) 0.0042 33.3 (23)
No 68.6 (921) 71.5 (4537) 76.4 (4630) 75.2 (3464) 72.1 (80) 73.8 (13632) 59.4 (41)
Missing 28.0 (375) 23.8 (1509) 20.2 (1225) 21.4 (987) 21.6 (24) 22.3 (4120) 7.3 (5)
Difficulty Chair
Yes 5.3 (71) 5.6 (354) 5.2 (312) 6.1 (279) 6.3 (7) 5.5 (1023) 0.6787 37.7 (26)
No 66.5 (892) 69.5 (4405) 72.9 (4421) 71.2 (3281) 68.5 (76) 70.8 (13075) 58.0 (40)
Missing 28.2 (379) 24.9 (1582) 21.9 (1330) 22.7 (1048) 25.2 (28) 23.7 (4367) 4.3 (3)
Walking Slower
Yes 8.4 (113) 16.1 (1024) 29.5 (1787) 47.0 (2165) 55.9 (62) 27.9 (5151) <0.0001 82.6 (57)
No 61.0 (818) 56.7 (3594) 47.2 (2862) 30.7 (1417) 18.0 (20) 47.2 (8711) 14.5 (10)
Missing 30.6 (411) 27.2 (1723) 23.3 (1414) 22.3 (1026) 26.1 (29) 24.9 (4603) 2.9 (2)
Micrographia
Yes 4.6 (62) 4.6 (294) 7.4 (446) 13.1 (604) 21.6 (24) 7.7 (1430) <0.0001 71.0 (49)
No 65.2 (875) 69.5 (4406) 70.6 (4283) 65.4 (3012) 54.1 (60) 68.5 (12636) 24.6 (17)
Missing 30.2 (405) 25.9 (1641) 22.0 (1334) 21.5 (992) 24.3 (27) 23.8 (4399) 4.4 (3)
Smell less acute
Yes 5.4 (73) 6.1 (388) 7.4 (450) 8.8 (407) 10.8 (12) 7.2 (1330) <0.0001 30.4 (21)
No 61.5 (825) 66.2 (4199) 68.7 (4164) 68.9 (3175) 65. 8 (73) 67.4 (12436) 56.5 (39)
Missing 33.1 (444) 27.7 (1754) 23.9 (1449) 22.3 (1026) 23.4 (26) 25.4 (4699) 13.1 (9)
Any of symptoms
Yes 15.7 (210) 20.6 (1306) 29.3 (1775) 39.6 (1826) 42.3 (47) 28.0 (5164) <0.0001 73.9 (51)
No 45.3 (608) 42.6 (2702) 34.2 (2074) 21.2 (977) 12.6 (14) 34.5 (6375) 2.9 (2)
Missing 39.0 (524) 36.8 (2333) 36.5 (2214) 39.2 (1805) 45. 1 (50) 37.5 (6926) 23.2 (16)
Self-reported PD 0.07 (1) 0.25 (16) 0.31 (19) 0.69 (32) 0.90 (1) 0.37 (69) <0.0001
*Calculated using chi-square for trend for each individual symptom across the age groups.Page 4 of 9
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was 91% and specificity 76%.
The prevalence of parkinsonian symptoms in the total
sub-cohort was similar for the age groups < 65 and 65+
years, with the exception of micrographia and walking
slower, which were reported twice as often by the older
age group (Table 6).
Discussion
The purpose of this paper was not to validate a possible
screening questionnaire, but to report the responses of the
EPIC cohort to questions about the prevalence of various
parkinsonian symptoms, and examine how these relate to
age and self-reported PD. Similar questionnaires have
been validated and various cut-off points used to identify
individuals for further examination in a two-step
screening process [5,6,21-32]. However, most of these did
not report the responses for each question, but instead
reported the sensitivity and specificity for a specific cho-
sen cut-off point. Sensitivity was often quite high, how-
ever the positive predictive value for Parkinson's disease
after screening was often low. Sensitivity and specificity
are reported for the questionnaire, with self-reported PD
as the disease outcome. Neurological examinations were
not conducted to validate diagnoses or to identify de novo
cases.
Study population
The current study population was a sub-cohort that com-
pleted the first follow-up questionnaire of the EPIC-Nor-
folk study. The population was restricted by age at
baseline (45–74 years) and was ethnically homogeneous.
The consequence of the homogeneous ethnicity and lim-
ited study area is that the results of this study may only be
generalizable to Caucasians of similar socio-economic
status and environmental conditions. Ethnic and geo-
graphical differences must be considered as possible
explanations for differences in prevalence between stud-
ies, once methodological differences are accounted for.
We have combined men and women for the analyses
because there were few PD cases, and age was considered
a more pertinent variable.
Selection bias was introduced at the original recruitment
of participants for EPIC and in the exclusion of
participants who had not answered the follow-up health
questionnaire. Individuals who were ill at baseline were
excluded from the study, and those who became ill after
the baseline exam would be more likely to have dropped
out of the study by the questionnaire at eighteen months.
The prevalence estimates from this study are expected to
be underestimates of the true measures in the Norfolk
population because the sub-cohort is healthier than the
general population and the original study population.
However, the expected number of 72 cases, as calculated
by indirect standardization using a prevalence study car-
ried out in general practices in London, is similar to the 69
prevalent cases identified in the EPIC sub-cohort [33].
A further attrition of participants occurred because 38% of
the sub-cohort did not respond to one or more of the
symptom questions. The number of missing responses
was associated with age, education, and smoking. All
Table 5: The sensitivity and specificity of the self-reported questionnaire for PD identified by self-report and routine records (N = 11 
539)
TP FN Sensitivity TN FP Specificity
Rest Tremor 26 27 49.1 11016 470 95.9
Difficulty Walking 19 34 35.9 11006 480 95.8
Difficulty Chair 21 32 39.6 10770 716 93.8
Walking Slower 45 8 84.9 7619 3867 66.3
Micrographia 39 14 73.6 10457 1029 91.0
Olfactory 
dysfunction
18 35 34.0 10442 1044 90.9
Any of 6 
symptoms
51 2 96.0 6373 5113 55.5
Any of symptoms 
except Walking 
slower
48 5 90.6 8684 2802 75.6
≥2 symptoms 46 7 86.8 9705 1781 84.5
≥3 symptoms 38 15 71.7 10930 556 95.2
≥4 symptoms 22 31 41.5 11363 123 98.9
≥5 symptoms 11 42 20.8 11455 31 99.7
TP = True Positive; FN = False Negative; TN = True Negative; FP = False PositivePage 5 of 9
(page number not for citation purposes)
BMC Neurology 2005, 5:15 http://www.biomedcentral.com/1471-2377/5/15analyses of symptom prevalence were conducted with the
subset of 62% of individuals who answered all questions,
and repeated assuming that missing answers indicated the
absence of the symptom.
Subjects missing the date of the second health examina-
tion were excluded to avoid an inconsistent denominator
for analyses. Among the excluded participants were less
than 3% of the sub-cohort, but this included 4 PD cases.
Methods
The questions regarding the presence of parkinsonian
symptoms were subject to participant interpretation and
relied on complete answers in the follow-up health ques-
tionnaire. The patterns of missing data according to the
order of the questions in the questionnaire showed that
most individuals answered all, none, all except one, or
only one of the questions. It is difficult to hypothesize
why individuals did not answer certain questions. Those
answering none of the questions or only the first symp-
toms question could be due to the format of the question-
naire. The first part of the question asks about the
Table 6: Prevalence (%) of parkinsonian symptoms in elderly populations, with and without parkinsonism, from screening 
questionnaire studies and current* study.
Total Populations
Current Mutch [4] Pramstaller [5] Rocca [6] Teresi [7]
Number of Subjects 6771 4768 87 36 16 164
Age (Years) <65 >65 71–76 40+ 62–96 65+
Symptom
Arms or legs ever shake? 5.0 35.0 6.2
Resting Tremor 3.8 5.0 9.9
Shuffle feet 3.0 8.3 31.2 10.1
Feet suddenly freeze in doorways 2.8 6.2
Poor balance 10.0 27.8 37.5
Difficulty Walking 4.7 3.8
Walking Slower 22.1 50.7 3.8#
Trouble rising from chair 6.4 6.4 13.0 13.9 37.5 21.4
Micrographia 6.0 13.9 14.0 5.6 12.5 13.2
Olfactory dysfunction 7.7 11.3
Patients with Parkinsonism
Current Duarte [28] Meneghini [31] Mutch [4] Pramstaller [5] Rocca [6]
Number of Subjects 53 36 21 35 40 37
Age (Years) 46–81 30–89 40+ 57–89 40+ 58–94
Symptom
Arms or legs ever shake? 89.1 76.2 77.0 65.0 64.9
Resting Tremor 49.1
Shuffle feet 72.9 51.0 82.5 67.6
Feet suddenly freeze in doorways 51.3 52.5 56.8
Poor balance 83.7 69.0 75.0 81.1
Difficulty Walking 35.9
Walking Slower 84.9
Trouble rising from chair 39.6 59.0 66.0 67.5 75.7
Micrographia 73.6 64.8 74.0 90.0 73.0
Olfactory dysfunction 34.0
*Current study including only the individuals who answered all symptoms questions (N = 11 539)
# Interviewer observationPage 6 of 9
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might improve the response if the symptoms questions
were asked first, so those without PD diagnoses would not
assume that the following questions did not apply to
them.
It was not possible to conduct neurological examinations
for all cohort participants, as Parkinson's disease is a sec-
ondary outcome for the EPIC-Norfolk study. However, a
review reports that self-rated health status has been shown
in many studies to be an accurate predictor of mortality,
even better than medical records [34]. Self-rated health
and self-reported parkinsonian symptoms are indeed two
different measures, however the review emphasizes the
value of self-report, even with its limitations. A cross-sec-
tional study reported correlation between mild parkinso-
nian symptoms, measured with a shortened version of the
UPDRS, and both self-reported measured of function and
performance-based test scores [35]. Some literature com-
paring self-report with neurological examination,
although not specifically for PD, offers further support
[36].
The PD ascertainment methods were incomplete and
relied heavily on the accuracy of self-report. PD self-report
can be assumed to be relatively accurate because it is a
serious condition without a negative social stigma [37-
40]. However, all ascertainment methods relied on a pre-
vious diagnosis of PD by medical practitioners, when it is
known that misdiagnosis in the community setting can be
greater than 25%, and underdiagnosis more than 20%
[33,41]. Another possible cause for underreporting was
that the baseline questionnaire did not specifically ask
about past diagnosis of PD, so the participant had to write
the disease in a part of the form to list 'other serious ill-
nesses.' Underascertainment and underdiagnosis would
dilute the observed difference in reported symptoms
between PD cases and controls because there would be
unidentified cases in the control group. However, the
control group is relatively large so the effect would be
minimal.
Sensitivity and specificity were calculated for each ques-
tion and combinations of questions, however the out-
come measure was self-reported PD. In the absence of a
true gold standard pathological marker for PD, a thor-
ough neurological examination by a movement disorders
specialist would be preferred. The measures in this study
show how well the self-reported symptom questions
relate to self-reported PD. De novo PD cases would not be
included in the cases, therefore the true sensitivity and
specificity of the questionnaire are unknown. The values
do give a good indication of which questions might not be
useful for distinguishing cases from controls, such as
slower walking.
Comparisons and conclusions
Although this study was not an evaluation of a screening
instrument, the studies reporting the responses to similar
questionnaires were all either for screening validation or
prevalence surveys [4-7,28,31]. Positive responses are
compared between the individuals in the sub-cohort who
answered all symptoms questions, for above and below
65 years of age, and the unaffected controls from other
studies. The symptom responses are also compared
between PD cases (Table 6). The proportion of individu-
als with complete responses reporting individual parkin-
sonian symptoms in the sub-cohort was approximately 4–
10% for resting tremor, difficulty walking, difficulty get-
ting out of a chair, micrographia, and olfactory
dysfunction. In addition, five studies conducted neurolog-
ical examinations to determine the presence of neurolog-
ical signs in elderly populations [1,8-11]. The
neurological signs tremor, gait disturbance, and shuffling
feet correspond with some of the previous questionnaire
symptoms, but only tremor was included in the current
study questionnaire.
If resting tremor and shaking of arms or legs are consid-
ered to be the same symptom, most of the questionnaire
studies report prevalence less than 10% except for the
35% reported by a relatively young control group in
Pramstaller et al [5]. There is a large range across the neu-
rological examination from 1% to 30%, which is not
explained by age. A number of differences could explain
the variation including the differences in study popula-
tions and assessment methods. Resting tremor was
reported by 42% of the cases, which is low compared to
the 75–90% reported in several other studies [42-45].
Some of the studies asked about tremor or shaking with-
out specifying that it was occurring at rest. If the tremor
question alone is used then 43 (81.1%) of PD cases and
888 (8%) of individuals with complete symptoms
responses answered positively.
Walking slower was the most commonly reported symp-
tom in cases and in all EPIC subjects who responded to all
questions. The only other study to report on this symptom
used interviewer observation rather than a questionnaire
for assessment, therefore the much lower prevalence in
that study is not truly comparable.
Trouble rising from a chair was reported less frequently by
EPIC participants with complete responses compared
with other questionnaires. The same was true for PD cases.
The presence of micrographia within EPIC corresponded
with other questionnaires for the two age groups, below
and above 65 years, and for PD patients. Difficulty walk-
ing was not specifically asked on comparison question-
naires, although other symptoms related to walking arePage 7 of 9
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reported by EPIC.
The lower prevalence of parkinsonian symptoms in the
EPIC sub-cohort compared to the previous studies could
be explained by selection bias for a healthy cohort,
although the observed prevalence of PD from self-report
was close to the expected prevalence of PD [33]. The lower
prevalence of symptoms in EPIC PD cases compared to
cases from other studies could be due to less severe or
more recently diagnosed disease in the EPIC participants,
although dates of diagnosis are not available at this time.
The age division of EPIC participants showed that only
walking slower and micrographic were much more fre-
quent in individuals above 65 years. The other symptoms
were similar in both groups, which is unexpected, how-
ever the questions may not be specific to the symptom of
interest since the question is dependent on individual
interpretation.
Despite the limitations of the study, there were important
findings concerning the reported prevalence of parkinso-
nian symptoms in the sub-cohort and stratified by self-
reported PD status. The results are not unexpected but it is
useful to support evidence that individual and cumulative
self-reported parkinsonian symptoms are strongly associ-
ated with self-reported PD diagnosis and increasing age.
The data also provide information regarding the preva-
lence of symptoms in a younger population of adults than
previously reported in the literature.
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